Monoclonal antibodies
The previously described (Hu et al, 1995) human-mouse chimaeric Lym-1 mAb (chLym-1) was used as anti-target mAb for the cytolytic assay. Moreover, the following mAbs were used: anti-CD32 IV.3 (Fab fragments, Medarex, West Lebanon, NH), anti-CD16 3G8 [F(ab′) 2 fragments, Medarex], anti-CD64 197 (mIgG2a, Medarex), anti-CD16 FITC-conjugated mAb 3G8 (IgG1, Pharmingen, San Diego, CA), anti-CD32 FITC-conjugated mAb FL18-26 (IgG2b, Pharmingen), anti-CD64 FITC-conjugated mAb 10.1 (IgG1, Pharmingen) and appropriate mouse IgG FITCconjugate isotype control 107.3 and 49.2 (Pharmingen).
Neutrophil preparation
Heparinized venous blood (heparin 10 U ml -1 ) was obtained from healthy volunteers and from patients receiving G-CSF treatment (G-CSF, Neupogen, 3-5 µg kg -1 for 3-5 days) after informed consent. No healthy donor had an infectious disease or was under medication at the time of and for 2 weeks before sampling. For patients receiving G-CSF therapy to alleviate chemotherapyinduced bone marrow toxicity and its clinical consequences, the following criteria for drawing blood samples were used: (a) at least 3 days of G-CSF therapy; (b) at least one day from the last G-CSF administration; (c) an absolute neutrophil count > 2500 µl -1 . Neutrophils were prepared by dextran sedimentation, followed by centrifugation (400 g, 30 min) on a Ficoll-Hypaque density gradient, as previously described (Ottonello et al, 1996) . Contaminating erythrocytes were removed by hypotonic lysis (Ottonello et al, 1996) . Neutrophils, resuspended in RPMI-FCS, were > 97% pure and > 98% viable as determined by assay described (Ottonello et al, 1996) .
Target cells
Lymphoblastoid Raji cells (Ottonello et al, 1996) were used as targets in the cytolytic assays. For cytolytic assays, 4 × 10 6 Raji cells were labelled with 100 to 200 µCi sodium chromate 51 Cr by incubating for 1 h at 37˚C (final volume 0.5 ml, medium: RPMI 1640 plus 5% FCS). After washing, labelled cells were resuspended in RPMI-FCS.
Cytolytic assays
Cytolytic activity of neutrophils was measured as described elsewhere in detail (Ottonello et al, 1996) . Briefly, target cells (2 × 10 4 ) were mixed with neutrophils at an effector : target ratio of 20:1, with and without chLym-1 monoclonal antibody and/or GM-CSF appropriately diluted in RPMI-FCS. The effector: target ratio of 20:1 was chosen on the basis of preliminary experiments. Experiments were carried out in the absence or presence of the various mAbs used to probe the cytolytic process. The assays were carried out in triplicate and in a final volume of 150 µl, using round bottom microplates (Falcon, Becton-Dickinson Italia, Milano, Italy) . After 14-h incubation in humidified atmosphere of 95% air and 5% CO 2 , the 51 Cr-release was determined in the cellfree supernatants. The percentage of cytolysis was calculated according to the formula 100 × (E-S)/(T-S), where E is the cpm released in the presence of effector cells, T is the cpm released after lysing target cells with 5% Triton X-100, and S is the cpm spontaneously released by target cells incubated with medium alone.
Immunofluorescence analysis
Purified neutrophils (1 × 10 6 cells in HBSS) were incubated for 30 min at 4˚C with 4 µg/ml mAbs specific for surface antigens or isotype mAb controls. Incubations were carried out in the presence of polyclonal human IgG (4 mg ml -1 ) to inhibit non-specific mAb binding to FcγRI. The cells were washed three times PBS supplemented with 1% bovine serum albumin and resuspended in PBS for analysis on a flow cytometer (EPICS Profile, Coulter). For each cell population, the relative fluorescence intensity (RFI) was calculated as the ratio of mean linear fluorescence intensity of relevant to irrelevant isotype controlled mAbs.
Statistical analysis
Results were expressed as mean ± 1 SD and/or a median with the 95% confidence interval. Statistical differences were analysed by Kruskal-Wallis nonparametric ANOVA test followed by Dunn's multiple comparisons test and by Mann-Whitney U-test. Significance was accepted when P < 0.05.
RESULTS

Lysis of Raji cell by normal neutrophils in the presence of chLym-1 and GM-CSF
When added to 51 Cr-labeled Raji cells in the presence of 10 µg ml -1 chLym-1, normal neutrophils induced low but detectable levels of target lysis, as measured by a 14-h 51 Cr release assay (Figure 1) . Moreover, the addition of 1 ng ml -1 GM-CSF consistently augmented neutrophil-mediated chLym-1-dependent cytolysis (Figure 1 ). Consistent with previous observation (1,3), normal neutrophils were incapable of mediating spontaneous lysis and failed to display activity in the presence of GM-CSF alone, i.e. in the absence of anti-target antibodies ( Figure 1 ). As shown in Figure 2 , GM-CSF stimulated chLym-1-dependent lysis was Cr-labelled Raji target cells were at 2 × 10 4 . The neutrophil: target ratio was 20 : 1. The incubation time was 14 h. Results are expressed as mean ± 1 SD. Nil (n = 14) vs. chLym-1 (n = 19): P < 0.01; chLym-1 (n = 19) vs chLym-1 + GM-CSF (n = 19): P < 0.05; GM-CSF (n = 14) vs chLym-1 + GM-CSF (n = 19): P < 0.001. Kruskal-Wallis nonparametric ANOVA test followed by Dunn's multiple comparisons test inhibited by 4 µg/ml mAb IV.3 (anti-CD32) and unaffected by 4 µg ml -1 mAb 3G8 (anti-CD16). These data suggest that CD32, i.e. Fcγ receptor type II (FcγRII) in instrumental for neutrophilmediated lysis. It is of note that when the cytolytic assay was carried out using 5 instead of 10 µg ml -1 chLym-1, the lysis was augmented significantly by mAb 3G8 (Figure 3 ). This suggests that, in the presence of relatively low concentrations of anti-target chLym-1 antibody, CD16, i.e. FcγRIII down-regulates neutrophil cytolytic efficiency.
Lysis of Raji cells by neutrophils from patients treated with G-CSF
As shown in Figure 4A , chLym-1 induced a dose-dependent Raji cells lysis by neutrophils from a representative patient treated with G-CSF. Moreover, the addition of 1 ng ml -1 GM-CSF enhanced neutrophil lytic efficiency ( Figure 4A ). Finally, when tested in the presence of 5 µg ml -1 chLym-1, the extent of the lysis was found to depend on the effector : target ratio both in the absence and in the presence of GM-CSF. On this basis, an effector target ratio of 20:1 and a chLym-1 concentration of 5 µg ml -1 were chosen for subsequent experiments. Figure 5 summarizes the results obtained by testing the activity of neutrophils from 15 patients treated with G-CSF. These cells exerted consistent levels of chLym-1 dependent lysis ( Figure 5 ). Moreover, GM-CSF enhanced significantly (P = 0.0042) the lytic efficiency, the level of lysis being 50% or more in the majority of the cases ( Figure 5 ). Finally, neutrophils from G-CSF treated patients displayed a level of CD64 (FcγRI) and CD32 (FcγRII) expression significantly higher than cells from normal donors (Figure 6) . The cells from G-CSF treated patients had also a CD16 (FcγRIII) surface expression lower than that shown by normal neutrophils (Figure 6 ).
Role of FcγR in the cytolysis mediated by neutrophils from patients treated with G-CSF
ChLym-1 dependent lysis by neutrophils from G-CSF treated patients, carried out in the presence of GM-CSF, was slightly but not significantly reduced by anti-CD64 mAb 197 (percent lysis: 46.25 ± 20.54 and 34.44 ± 13.81 in the absence and presence of 4 µg ml -1 mAb 197 respectively, mean ± 1 SD, n = 6; P = 0.393). Similarly, a nonsignificant inhibition was observed by adding 4 µg ml -1 of mAb IV.3 specific for CD32 (percent lysis: 40.37 ± 16.35 and 28.84 ± 23.22 in the absence or presence of mAb IV.3 respectively, mean ± 1 SD, n = 5; P = 0.309). On the contrary, the lysis was significantly inhibited by the simultaneous addition of both mAb 197 and IV.3 to the system (Figure 7 ), whereas no effect was detectable by using the anti-CD16 mAb 3G8 (Figure 7) . Similarly, neither mAb 197 nor mAb IV.3 inhibited the lysis mediated by neutrophils from G-CSF treated patients in the absence of GM-CSF (not shown), whereas the two mAbs added simultaneously were effective (Figure 8 ). In addition, as shown in Figure 8 , the presence of anti-CD16 mAb 3G8 significantly enhanced chLym-1 dependent lysis, exerted by neutrophils from G-CSF treated patients incubated with target cells in the absence of GM-CSF. 
DISCUSSION
The present study shows that: (a) human-mouse chimaeric Lym-1 mAb (chLym-1) is capable of triggering low level of cytolytic activity in normal neutrophils through a process highly susceptible of amplification by GM-CSF; (b) neutrophils from patients treated with G-CSF display chLym-1 dependent cytolytic activities higher than those achievable with normal effector cells and susceptible to be further stimulated with GM-CSF; (c) normal neutrophils exert their activity via FcγRII (CD32) whereas cells from G-CSF treated patients act by using both FcγRII (CD32) and FcγRI (CD64); (d) the efficiency of neutrophils from normal donors and that of cells from G-CSF treated patients appears to be sensitive to a downregulation by FcγRIII (CD16).
Previous studies from various research groups have shown that neutrophils from G-CSF treated patients are more efficient that those from healthy donors in mediating the lysis of various tumour cells sensitised with polyclonal rabbit antiserum (Repp et al, 1991) or murine monoclonal antibodies (Elsässer et al, 1996; Michon et al, 1998; Valerius et al, 1993; Würflein et al, 1998) . Among these studies, the findings of Elsaässer and co-workers (Elsässer et al, 1996) and those of Würflein and co-workers (Würflein et al, 1998) are closely related to the present ones. In fact, these authors found that G-CSF primed neutrophils are more effective than healthy donor neutrophils against Raji target cells sensitised with murine Lym-1. The present observations extend these findings, showing that the phenomenon occurs also by replacing murine Lym-1 with chimaeric Lym-1 (chLym-1). Moreover, in agreement with our previous observations obtained with murine Lym-1 (Ottonello et al, 1996) , the exposure of normal neutrophils to GM-CSF resulted in stimulated chLym-1 dependent cytolysis. The stimulation by GM-CSF was also found using G-CSF primed neutrophils, a finding particularly interesting also taking into account the level of lysis achievable. Twelve of the fifteen cases studied were indeed characterized by a GM-CSF stimulated chLym-1 dependent lysis of 50% or higher. Moreover, three of these cases had a lytic activity higher than 75%. Therefore, it appears that in vivo administration of G-CSF induces a population of circulating neutrophils particularly prone to exert chmAbdependent cytolysis and susceptible to further stimulation by GM-CSF.
Several papers dealing with the role of distinct FcγRs in murine mAb-dependent tumour cell lysis by normal neutrophils have shown the involvement of FcγRII (Würflein et al, 1998) or FcγRIII (Gavioli et al, 1991) or both (Kushner and Cheung, 1989; Kushner and Cheung, 1992) . Our previous observations carried out with murine Lym-1 and Raji target cells (Ottonello et 1999) and the presents findings with the human-mouse chimaeric construct of this mAb suggest that normal neutrophils use FcγRII for mediating cytolysis. In general, this is also consistent with the well-recognized role of this receptor as effective cytolytic trigger molecule in neutrophil-mediated lysis of anti-FcγRII antibodybearing hybridoma cells (Elsässer et al, 1996; Graziano and Fanger, 1990 ). Relatively few data are available on the interaction of different FcγRs in cytolysis by neutrophils from subjects treated with G-CSF (Elsässer et al, 1996; Würflein et al, 1998) and, to our knowledge, data for the chLym-1 system are lacking. In contrast to healthy donor neutrophils, which express FcγRII and FcγRIII constitutively, G-CSF primed cells additionally express the highaffinity FcγRI (Kerst et al, 1993; Michon et al, 1998; Repp et al, 1991) . Although, as herein confirmed, the expression of the FcγRI is relatively lower than that the other FcγRs (Kerst et al, 1993; Michon et al, 1998; Repp et al, 1991) , its intervention in murine mAb-dependent tumour cell lysis by G-CSF primed neutrophils takes place and depends on the isotype of the target-sensitising mAb (Würflein et al, 1998) . In particular, the lysis of Raji target cells sensitized with mouse-murine chimaeric IgG1 mAb F3.3 to HLA-class II by G-CSF primed neutrophils was found to be partially but not significantly inhibited by blocking FcγRI with mAb 197 (~ 40% inhibition) and FcγRII with mAb IV.3 (~ 15% inhibition) (Würflein et al, 1998) . The present experiments with chLym-1 extend these observations. In fact, the IgG1 chLym-1-dependent lysis by G-CSF-primed neutrophils, both in the absence and presence of GM-CSF, was partially and not significantly reduced by mAb 197 as well as mAb IV.3, but significantly inhibited by the two anti-FcγR mAbs used simultaneously. Therefore, FcγRI and FcγRII cooperate to trigger G-CSF primed neutrophils, undergoing direct as well as GM-CSF-stimulated chmAb-dependent lysis.
It is well known that CD16, i.e. FcγRIII is the most abundant neutrophil receptor for the Fc portion of IgG (Gessner et al, 1998; Unkeless, 1989) . This receptor is coupled to a phosphatidylinositol anchor (Gessner et al, 1998; Unkeless, 1989) and, via interaction with CD11b-CD18 integrins, activates certain phagocytic effector functions such as phagocytosis and related neutrophil responses including the respiratory burst (Porter and Hogg, 1998; Todd and Petty, 1997; Zhou and Brown, 1994) . Nevertheless, evidence for its involvement as cytotoxic trigger in neutrophil-mediated mAbdependent tumour cell lysis is presently lacking (Elsässer et al, 1996; Ottonello et al, 1999) . On the contrary, the present results suggest that the anti-FcγRIII mAb 3G8 can augment chLym-1 dependent neutrophil induced cytolysis. Therefore, it appears that FcγRIII may moderate the FcγRI-and FcγRII-mediated neutrophil response to mAb-sensitized targets. In this view, the ability of G-CSF to reduce the expression of FcγRIII might conceivably cooperate with the ability of G-CSF to induce FcγRI in order to provide neutrophils with enhanced mAb-dependent potential. In agreement with and related to these concepts, it has been suggested that shedding of FcγRIII during neutrophil activation may permit a more efficient binding of IgG-opsonized phagocytosable targets to receptors, such as FcγRII, that are primarily responsible for the triggering the lytic machinery of the neutrophil (Huizinga et al, 1990) . . Cytolysis in the absence vs that in presence of 4 µg ml -1 mAb IV.3 plus 4 µg ml -1 mAb 197: P = 0.0159. Mann-Whitney U-test
In conclusion, the present study provides rational bases for raising optimized adjuvant immune-interventions in B-lymphomas, based on combined administration of chLym-1 and cytokines such as G-CSF and GM-CSF, for instance, by including G-CSF treatment prior to and GM-CSF treatment during mAb administration. . Cytolysis in the absence vs that in presence of 4 µg ml -1 mAb IV.3 plus 4 µg ml -1 mAb 197: P = 0.0286. Cytolysis in the absence vs that in presence of 4 µg ml -1 mAb 3G8: P = 0.0286. Mann-Whitney U-test
